Advertisement

Medical Oncology

, 36:96 | Cite as

A novel role mediated by adenoviral E1A in suppressing cancer through modulating decorin

  • Yan Ge
  • Wen Zhang
  • Jing Qin
  • Chen Zhang
  • Weiping Tian
  • Qi Zhang
  • Jie Shao
  • Shasha Li
  • Lin FangEmail author
  • Junnian ZhengEmail author
Original Paper
  • 64 Downloads

Abstract

Oncolytic adenovirus is an emerging alternative to current therapeutics. The adenoviral E1A, the first protein expressed upon oncolytic adenoviral infection, has been identified as an antitumor agent, but the mechanisms of its tumor inhibition ability are unclear enough. Decorin is ubiquitous in the extracellular matrix (ECM), which regulates multiple functions through interaction with ECM. Here, we intended to explore the effects of adenoviral E1A on the tumor extracellular matrix during gene therapy. We demonstrated that reduced decorin expression was found in patients with lung cancer. The adenoviral E1A or a mutant adenoviral E1A with Rb-binding ability absent (E1A 30–60aa, 120–127aa deletion) could increase the expression of decorin and down-regulate VEGF, two members of tumor ECM, involved in both vasculogenesis and angiogenesis. E1A/mE1A-mediated suppressing the migration and invasion ability of tumor cells was depended on decorin. E1A interacted with decorin directly and induced the proteasomal degradation of VEGF. In addition, E1A or mE1A can inhibit tumor growth in a subcutaneous lung cancer xenograft model. It suggested that decorin might be a crucial mediator among ECM components for adenoviral E1A-mediated antitumor activities. These studies on adenovirus E1A provide a new mechanism for the emerging therapies of tumor gene therapy.

Keywords

Adenoviral E1A Decorin VEGF Extracellular matrix Lung carcinoma 

Notes

Acknowledgements

This project is supported by grants from the National Key Research and Development Plan (2018YFA0900900), the National Natural Science Foundation of China (Grant Nos. 81872488, 81372460), the Natural Science Foundation of Jiangsu Province (Grants Nos. BK20161156, BK20161157), the Education Department of Jiangsu Province (Grant Nos. 13KJB320028, 12KJA320001), Social Development Key Project of Jiangsu Province (Grant Nos. BE2016643), Jiangsu Provincial Medical Youth Talent (Grant Nos. QNRC2016774, QNRC2016773, CXTDA2017034, The Project of Invigorating Health Care through Science, Technology and Education) and Jiangsu Provincial Key Medical Discipline, The Project of Invigorating Health Care through Science, Technology and Education (No. ZDXKA2016014).

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Animal welfare and experimental procedures were carried out strictly in accordance with Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) and all procedures performed in studies involving animals were in accordance with the ethical standards of the Animal Care Committee of the Xuzhou Medical University, Xuzhou, China.

References

  1. 1.
    Yano T, Kawashima O, Takeo S, Adachi H, Tagawa T, Fukuyama S, et al. A prospective observational study of pulmonary resection for non-small cell lung cancer in patients older than 75 years. Semin Thorac Cardiovasc Surg. 2017;29(4):540–7.  https://doi.org/10.1053/j.semtcvs.2017.05.004.CrossRefPubMedGoogle Scholar
  2. 2.
    Dayen C, Debieuvre D, Molinier O, Raffy O, Paganin F, Virally J, et al. New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases. J Thorac Dis. 2017;9(12):5101–11.  https://doi.org/10.21037/jtd.2017.11.52.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene Laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol. 2017;18(1):1–15.  https://doi.org/10.1007/s40257-016-0238-9.CrossRefPubMedGoogle Scholar
  4. 4.
    Radko S, Koleva M, James KM, Jung R, Mymryk JS, Pelka P. Adenovirus E1A targets the DREF nuclear factor to regulate virus gene expression, DNA replication, and growth. J Virol. 2014;88(22):13469–81.  https://doi.org/10.1128/JVI.02538-14.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Su JL, Chen PB, Chen YH, Chen SC, Chang YW, Jan YH, et al. Downregulation of microRNA miR-520 h by E1A contributes to anticancer activity. Cancer Res. 2010;70(12):5096–108.  https://doi.org/10.1158/0008-5472.CAN-09-4148.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chen HA, Chang YW, Tseng CF, Chiu CF, Hong CC, Wang W, et al. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer. Ann Surg Oncol. 2015;22(3):889–98.  https://doi.org/10.1245/s10434-014-4061-3.CrossRefPubMedGoogle Scholar
  7. 7.
    Li Z, Day CP, Yang JY, Tsai WB, Lozano G, Shih HM, et al. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Can Res. 2004;64(24):9080–5.  https://doi.org/10.1158/0008-5472.CAN-04-2419.CrossRefGoogle Scholar
  8. 8.
    Fang L, Cheng Q, Zhao J, Ge Y, Zhu Q, Zhao M, et al. A p53-independent apoptotic mechanism of adenoviral mutant E1A was involved in its selective antitumor activity for human cancer. Oncotarget. 2016;7(30):48309–20.  https://doi.org/10.18632/oncotarget.10221.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Fang L, Cheng Q, Bai J, Qi YD, Liu JJ, Li LT, et al. An oncolytic adenovirus expressing interleukin-24 enhances antitumor activities in combination with paclitaxel in breast cancer cells. Mol Med Rep. 2013;8(5):1416–24.  https://doi.org/10.3892/mmr.2013.1680.CrossRefPubMedGoogle Scholar
  10. 10.
    Jiang G, Jiang AJ, Cheng Q, Tian H, Li LT, Zheng JN. A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis. Tumour Biol. 2013;34(2):1263–71.  https://doi.org/10.1007/s13277-013-0701-7.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang W, Ge Y, Cheng Q, Zhang Q, Fang L, Zheng J. Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment. Oncotarget. 2018;9(4):5480–91.  https://doi.org/10.18632/oncotarget.23869.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gubbiotti MA, Vallet SD, Ricard-Blum S, Iozzo RV. Decorin interacting network: a comprehensive analysis of decorin-binding partners and their versatile functions. Matrix Biol. 2016;55:7–21.  https://doi.org/10.1016/j.matbio.2016.09.009.CrossRefPubMedGoogle Scholar
  13. 13.
    Bierbaum S, Douglas T, Hanke T, Scharnweber D, Tippelt S, Monsees TK, et al. Collageneous matrix coatings on titanium implants modified with decorin and chondroitin sulfate: characterization and influence on osteoblastic cells. J Biomed Mater Res A. 2006;77(3):551–62.  https://doi.org/10.1002/jbm.a.30572.CrossRefPubMedGoogle Scholar
  14. 14.
    Bi XL, Yang W. Biological functions of decorin in cancer. Chin J Cancer. 2013;32(5):266–9.  https://doi.org/10.5732/cjc.012.10301.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005;5(12):965–76.  https://doi.org/10.1038/nrc1750.CrossRefPubMedGoogle Scholar
  16. 16.
    Choi IK, Lee YS, Yoo JY, Yoon AR, Kim H, Kim DS, et al. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther. 2010;17(2):190–201.  https://doi.org/10.1038/gt.2009.142.CrossRefPubMedGoogle Scholar
  17. 17.
    Goetsch KP, Niesler CU. The extracellular matrix regulates the effect of decorin and transforming growth factor beta-2 (TGF-beta2) on myoblast migration. Biochem Biophys Res Commun. 2016;479(2):351–7.  https://doi.org/10.1016/j.bbrc.2016.09.079.CrossRefPubMedGoogle Scholar
  18. 18.
    Yao T, Zhang CG, Gong MT, Zhang M, Wang L, Ding W. Decorin-mediated inhibition of the migration of U87MG glioma cells involves activation of autophagy and suppression of TGF-beta signaling. FEBS Open Bio. 2016;6(7):707–19.  https://doi.org/10.1002/2211-5463.12076.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Shi X, Liang W, Yang W, Xia R, Song Y. Decorin is responsible for progression of non-small-cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol. 2015;36(5):3345–54.  https://doi.org/10.1007/s13277-014-2968-8.CrossRefPubMedGoogle Scholar
  20. 20.
    Liang S, Xu JF, Cao WJ, Li HP, Hu CP. Human decorin regulates proliferation and migration of human lung cancer A549 cells. Chin Med J (Engl). 2013;126(24):4736–41.Google Scholar
  21. 21.
    Wu Y, Xiao T, Li M, Zhang Y, Gao Y, Sun K. Decorin protein is down-regulated in non-small cell lung cancer tissue and significantly associated with histological type. Zhongguo Fei Ai Za Zhi. 2011;14(11):848–52.  https://doi.org/10.3779/j.issn.1009-3419.2011.11.03.CrossRefPubMedGoogle Scholar
  22. 22.
    Xu L, Wang F, Liu H, Xu XF, Mo WH, Xia YJ, et al. Increased expression of cellular repressor of E1A-stimulated gene (CREG) in gastric cancer patients: a mechanism of proliferation and metastasis in cancer. Dig Dis Sci. 2011;56(6):1645–55.  https://doi.org/10.1007/s10620-010-1510-0.CrossRefPubMedGoogle Scholar
  23. 23.
    Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Can Res. 2001;61(16):6012–9.Google Scholar
  24. 24.
    Marshall KS, Cohen MJ, Fonseca GJ, Todorovic B, King CR, Yousef AF, et al. Identification and characterization of multiple conserved nuclear localization signals within adenovirus E1A. Virology. 2014;454–455:206–14.  https://doi.org/10.1016/j.virol.2014.02.020.CrossRefPubMedGoogle Scholar
  25. 25.
    Yu D, Hung MC. The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. Cancer Metast Rev. 1998;17(2):195–202.CrossRefGoogle Scholar
  26. 26.
    Fang L, Huang Y, Hu X, Sun L, He X, Hu H, et al. A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function. Chem Biol Interact. 2009;181(1):1–7.  https://doi.org/10.1016/j.cbi.2009.06.002.CrossRefPubMedGoogle Scholar
  27. 27.
    Su CM, Chang TY, Hsu HP, Lai HH, Li JN, Lyu YJ, et al. A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer. Oncotarget. 2016;7(39):63924–36.  https://doi.org/10.18632/oncotarget.11737.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Flinterman MB, Mymryk JS, Klanrit P, Yousef AF, Lowe SW, Caldas C, et al. p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing. Oncogene. 2007;26(48):6863–74.  https://doi.org/10.1038/sj.onc.1210497.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yamasaki Y, Tazawa H, Hashimoto Y, Kojima T, Kuroda S, Yano S, et al. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Eur J Cancer. 2012;48(14):2282–91.  https://doi.org/10.1016/j.ejca.2011.12.020.CrossRefPubMedGoogle Scholar
  30. 30.
    Das S, El-Deiry WS, Somasundaram K. Regulation of the p53 homolog p73 by adenoviral oncogene E1A. J Biol Chem. 2003;278(20):18313–20.  https://doi.org/10.1074/jbc.M211704200.CrossRefPubMedGoogle Scholar
  31. 31.
    Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, et al. FOXO3a-dependent mechanism of E1A-induced chemosensitization. Can Res. 2011;71(21):6878–87.  https://doi.org/10.1158/0008-5472.CAN-11-0295.CrossRefGoogle Scholar
  32. 32.
    Liao Y, Zou YY, Xia WY, Hung MC. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. Cancer Gene Ther. 2004;11(9):594–602.  https://doi.org/10.1038/sj.cgt.7700743.CrossRefPubMedGoogle Scholar
  33. 33.
    Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000;6(1):250–9.PubMedGoogle Scholar
  34. 34.
    King CR, Zhang A, Tessier TM, Gameiro SF, Mymryk JS. Hacking the cell: network intrusion and exploitation by adenovirus E1A. mBio. 2018.  https://doi.org/10.1128/mBio.00390-18.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Deissler H, Opalka B. Therapeutic transfer of DNA encoding adenoviral E1A. Recent Pat Anticancer Drug Discov. 2007;2(1):1–10.CrossRefGoogle Scholar
  36. 36.
    Buraschi S, Neill T, Iozzo RV. Decorin is a devouring proteoglycan: remodeling of intracellular catabolism via autophagy and mitophagy. Matrix Biol. 2019;75–76:260–70.  https://doi.org/10.1016/j.matbio.2017.10.005.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Cancer Institute, Xuzhou Medical UniversityXuzhouChina
  2. 2.Center of Clinical OncologyAffiliated Hospital of Xuzhou Medical UniversityXuzhouChina
  3. 3.Jiangsu Key Laboratory of Biological Cancer TherapyXuzhou Medical UniversityXuzhouChina

Personalised recommendations